AC Immune SA (ACIU) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACIU SEC filings page.
AC Immune SA (ACIU) reported $4.5M in revenue for fiscal year 2025, down 85.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AC Immune SA's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for AC Immune SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
AC Immune SA had 102M shares outstanding at the end of fiscal year 2025, against 100M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and AC Immune SA scores 68/100 among other emerging companies.
AC Immune SA spent $71.1M on research and development in fiscal year 2025, which was 77.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and AC Immune SA scores 94/100 among other emerging companies.
AC Immune SA reported revenue of $4.5M in fiscal year 2025, against $30.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and AC Immune SA scores 6/100 among other emerging companies.
AC Immune SA's operations used $87.3M of cash in fiscal year 2025, against $72.6M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and AC Immune SA scores 37/100 among other emerging companies.
Not available for AC Immune SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
AC Immune SA scores -4.40, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $553.2M against total assets of $194.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
AC Immune SA passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
AC Immune SA reported a net loss of $88.8M while operations used $87.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
AC Immune SA reported an operating loss of $87.3M against $241K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
AC Immune SA generated $4.5M in revenue in fiscal year 2025. This represents a decrease of 85.1% from the prior year.
AC Immune SA reported a net loss of $88.8M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
AC Immune SA recorded an outflow of $88.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 222.8% from the prior year.
AC Immune SA held $33.8M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
AC Immune SA's ROE was -156.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 111.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
AC Immune SA invested $71.1M in research and development in fiscal year 2025. This represents an increase of 3.1% from the prior year.
AC Immune SA invested $1.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 78.5% from the prior year.
Not reported for fiscal year 2025.
ACIU Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M-85.1% | $30.1M+71.0% | $17.6M+313.5% | $4.3Mn/m | $0-100.0% | $17.5M-84.7% | $114.1M+1523.6% | $7.0M-66.2% | $20.8M-9.0% | $22.8M-41.4% | $39.0M |
| R&D Expenses | $71.1M+3.1% | $69.0M+6.2% | $65.0M-0.5% | $65.3M-4.1% | $68.1M+1.2% | $67.3M+29.1% | $52.1M+15.7% | $45.0M+34.3% | $33.5M+32.2% | $25.4M+49.0% | $17.0M |
| Operating Income | -$87.3Mn/m | -$57.8Mn/m | -$63.8Mn/m | -$76.7Mn/m | -$86.4Mn/m | -$69.3M-250.6% | $46.0Mn/m | -$50.4Mn/m | -$23.1Mn/m | -$10.3M-155.4% | $18.6M |
| Interest Expense | $241K+64.1% | $147K-30.0% | $209K-45.5% | $384K-39.5% | $635K+205.2% | $208K-89.4% | $2.0M+545.8% | $303K+100.8% | $151K+2091.0% | $7Kn/m | $0 |
| Income Tax | $0-100.0% | $3K-72.2% | $12K-15.4% | $14K+328.9% | $3Kn/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Net Income | -$88.8Mn/m | -$56.1Mn/m | -$64.5Mn/m | -$76.6Mn/m | -$79.8Mn/m | -$70.0M-249.1% | $47.0Mn/m | -$51.8Mn/m | -$27.1Mn/m | -$7.0M-134.5% | $20.2M |
| EPS (Basic) | N/A | N/A | N/A | N/A | N/A | -$0.97-247.1% | $0.66n/m | -$0.83n/m | -$0.47n/m | -$0.14-129.4% | $0.47 |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | -$0.97-247.1% | $0.66n/m | -$0.83n/m | -$0.47n/m | -$0.14-131.4% | $0.44 |
| Diluted Shares (Avg) | 101M+1.1% | 100M+17.7% | 85M+1.4% | 84M+11.5% | 75M+4.2% | 72M+1.1% | 71M+15.0% | 62M+8.3% | 57M+13.9% | 50M+8.8% | 46M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, EBITDA.
ACIU Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $194.4M-23.7% | $254.6M+17.1% | $217.5M+8.1% | $201.2M-29.6% | $285.9M+5.9% | $270.0M-12.7% | $309.2M+54.7% | $199.9M+47.5% | $135.6M-11.8% | $153.6M | N/A |
| Current Assets | $121.9M-35.7% | $189.7M+27.4% | $148.9M+7.4% | $138.6M-37.4% | $221.6M-15.5% | $262.2M-13.4% | $302.5M+54.2% | $196.2M+47.5% | $133.0M-12.7% | $152.5M | N/A |
| Cash & Equivalents | $33.8M-15.6% | $40.0M-57.2% | $93.4M+173.2% | $34.2M-62.0% | $89.9M-50.6% | $182.0M-9.0% | $200.0M+25.7% | $159.1M+24.6% | $127.7M-14.7% | $149.8M+96.1% | $76.4M |
| Total Liabilities | $137.8M+5.3% | $130.8M+396.0% | $26.4M+43.8% | $18.3M-43.1% | $32.2M+22.4% | $26.3M-5.0% | $27.7M+43.9% | $19.3M+23.6% | $15.6M+15.4% | $13.5M | N/A |
| Current Liabilities | $119.3M+7.3% | $111.2M+588.5% | $16.2M+30.0% | $12.4M-43.3% | $21.9M+38.1% | $15.9M-12.4% | $18.1M+36.0% | $13.3M+32.8% | $10.0M+2.6% | $9.8M | N/A |
| Non-Current Liabilities | $18.5M-5.8% | $19.6M+92.0% | $10.2M+72.9% | $5.9M-42.7% | $10.3M-1.3% | $10.5M+8.8% | $9.6M+61.5% | $6.0M+6.9% | $5.6M+48.9% | $3.7M | N/A |
| Total Equity | $56.6M-54.3% | $123.8M-35.2% | $191.1M+4.5% | $182.9M-27.9% | $253.6M+4.1% | $243.7M-13.4% | $281.5M+55.8% | $180.7M+50.6% | $120.0M-14.4% | $140.1M+97.6% | $70.9M |
| Retained Earnings | -$553.2Mn/m | -$406.1Mn/m | -$376.2Mn/m | -$285.7Mn/m | -$219.7Mn/m | -$150.3Mn/m | -$78.0Mn/m | -$124.0Mn/m | -$74.6Mn/m | -$46.2M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
ACIU Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$87.3M-220.2% | $72.6Mn/m | -$71.9Mn/m | -$79.6Mn/m | -$71.8Mn/m | -$67.3M-218.0% | $57.1Mn/m | -$44.8Mn/m | -$22.7Mn/m | -$5.6M-112.6% | $44.0M |
| Capital Expenditures | $1.1M+78.5% | $635K-33.3% | $953K-28.9% | $1.3M-53.5% | $2.9M+49.3% | $1.9M-0.9% | $1.9M+3.1% | $1.9M+2.1% | $1.9M+109.1% | $885K+263.3% | $244K |
| Free Cash Flow | -$88.4M-222.8% | $72.0Mn/m | -$72.8Mn/m | -$81.0Mn/m | -$74.7Mn/m | -$69.2M-225.6% | $55.1Mn/m | -$46.7Mn/m | -$24.5Mn/m | -$6.4M-114.7% | $43.8M |
| Investing Cash Flow | $80.1Mn/m | -$116.1M-248.7% | $78.1M+203.7% | $25.7Mn/m | -$58.7M-283.1% | $32.0Mn/m | -$69.1Mn/m | -$32.6Mn/m | -$1.9Mn/m | -$885Kn/m | -$244K |
| Financing Cash Flow | -$1.3Mn/m | -$1.2M-102.4% | $51.5Mn/m | -$1.5M-103.3% | $44.6Mn/m | -$908K-101.8% | $51.3M-53.9% | $111.2M+39875.0% | $278K-99.6% | $77.5M+179.6% | $27.7M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
ACIU Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1940.1% | -191.8% | -362.3% | -1800.4% | N/A | -397.0% | 40.3% | -716.9% | -111.3% | -45.0%-92.7pp | 47.6% |
| Net Margin | -1971.6% | -186.4% | -366.4% | -1798.0% | N/A | -401.3% | 41.1% | -737.1% | -130.4% | -30.6%-82.4pp | 51.8% |
| Return on Equity | -156.9%-111.6pp | -45.4%-11.6pp | -33.8%+8.1pp | -41.9%-10.4pp | -31.5%-2.7pp | -28.7%-45.4pp | 16.7%+45.4pp | -28.7%-6.1pp | -22.6%-17.6pp | -5.0%-33.5pp | 28.5% |
| Return on Assets | -45.7%-23.6pp | -22.1%+7.6pp | -29.7%+8.4pp | -38.0%-10.1pp | -27.9%-2.0pp | -25.9%-41.1pp | 15.2%+41.1pp | -25.9%-5.9pp | -20.0%-15.5pp | -4.5% | N/A |
| Current Ratio | 1.02-0.7x | 1.71-7.5x | 9.22-1.9x | 11.16+1.0x | 10.12-6.4x | 16.53-0.2x | 16.72+2.0x | 14.75+1.5x | 13.28-2.3x | 15.61 | N/A |
| Liabilities-to-Equity | 2.44+1.4x | 1.06+0.9x | 0.140.0x | 0.100.0x | 0.130.0x | 0.110.0x | 0.100.0x | 0.110.0x | 0.130.0x | 0.10 | N/A |
| Asset Turnover | 0.02-0.1x | 0.120.0x | 0.08+0.1x | 0.020.0x | 0.00-0.1x | 0.06-0.3x | 0.37+0.3x | 0.04-0.1x | 0.150.0x | 0.15 | N/A |
| FCF Margin | -1963.7% | 239.0% | -413.5% | -1901.1% | N/A | -396.8% | 48.3% | -664.6% | -118.0% | -28.2% | 112.1% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AC Immune SA ACIU | FY2025 | $4.5M | -$88.8M | N/A | $235.6M | 51/100 |
| Voyager Therapeutics, Inc. VYGR | FY2025 | $40.4M | -$119.7M | N/A | $108.4M | 57/100 |
| Editas Medicine, Inc. EDIT | FY2025 | $40.5M | -$160.1M | N/A | $450.0M | 44/100 |
| Immutep Limited IMMP | FY2025 | $6.8M | -$40.4M | N/A | $24.5M | 62/100 |
| ProQR Therapeutics N.V. PRQR | FY2025 | $18.7M | -$49.5M | N/A | $203.2M | 72/100 |
| Silence Therapeutics Plc SLN | FY2025 | $559K | -$88.6M | N/A | $1.2B | — |
Where AC Immune SA Ranks
Frequently Asked Questions
What is AC Immune SA's annual revenue?
AC Immune SA (ACIU) reported $4.5M in total revenue for fiscal year 2025. This represents a -85.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AC Immune SA's revenue growing?
AC Immune SA (ACIU) revenue declined by 85.1% year-over-year, from $30.1M to $4.5M in fiscal year 2025.
Is AC Immune SA profitable?
No, AC Immune SA (ACIU) reported a net loss of $88.8M in fiscal year 2025.
What is AC Immune SA's return on equity (ROE)?
AC Immune SA (ACIU) has a return on equity of -156.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is AC Immune SA's free cash flow?
AC Immune SA (ACIU) recorded an outflow of $88.4M in free cash flow during fiscal year 2025. This represents a -222.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AC Immune SA's operating cash flow?
AC Immune SA (ACIU) recorded an outflow of $87.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are AC Immune SA's total assets?
AC Immune SA (ACIU) had $194.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are AC Immune SA's capital expenditures?
AC Immune SA (ACIU) invested $1.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does AC Immune SA spend on research and development?
AC Immune SA (ACIU) invested $71.1M in research and development during fiscal year 2025.
What is AC Immune SA's current ratio?
AC Immune SA (ACIU) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.
What is AC Immune SA's liabilities-to-equity ratio?
AC Immune SA (ACIU) had a liabilities-to-equity ratio of 2.44 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is AC Immune SA's return on assets (ROA)?
AC Immune SA (ACIU) had a return on assets of -45.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is AC Immune SA's P/E ratio?
AC Immune SA (ACIU) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $235.6M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AC Immune SA's price-to-sales ratio?
AC Immune SA (ACIU) trades at 52.3x sales, its market capitalization divided by $4.5M revenue, FY2025. The market capitalization is $235.6M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AC Immune SA's Altman Z-Score?
AC Immune SA (ACIU) has an Altman Z-Score of -4.40, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is AC Immune SA's Piotroski F-Score?
AC Immune SA (ACIU) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AC Immune SA's earnings high quality?
AC Immune SA (ACIU) reported a net loss of $88.8M while operations used $87.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can AC Immune SA cover its interest payments?
AC Immune SA (ACIU) reported an operating loss of $87.3M against $241K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is AC Immune SA?
AC Immune SA (ACIU) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For AC Immune SA it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.